Viking Therapeutics: Phase-3 Studies for Obesity Candidate Underway – Stock Volatile

Viking Therapeutics Inc. (VKTX) is currently conducting Phase-3 studies for its leading anti-obesity candidate. The biotech company is thereby positioning itself in the growing market for weight loss medications, which has gained significant importance in recent years.

Current Stock Price Movements Show High Volatility

The VKTX stock experienced significant price fluctuations in the second quarter of 2026. On June 4, 2026, the stock closed at $29.78, representing an increase of 1.53% compared to the previous day. Two months earlier, on April 6, 2026, the stock had traded at $33.93 – on that trading day it fell by 2.5%.

The stock experienced a sharper decline on March 30, 2026, when it fell 7.95% to $29.94. The price movements demonstrate the typical volatility of biotech companies in advanced clinical development phases, where investors await study results and regulatory decisions.

Phase-3 Studies as a Critical Development Stage

The company is in Phase-3 studies with its anti-obesity candidate. This clinical phase represents the final testing phase before a potential approval and examines efficacy and safety in a larger patient population. Phase-3 studies are critical for evaluation by regulatory authorities such as the U.S. FDA or the European EMA.

The market for obesity medications has gained considerable momentum in recent years through the success of GLP-1 agonists. Companies that successfully develop medications in this segment face a potentially large sales market.

Analyst Ratings and Market Potential

In June 2026, analysts discussed whether the VKTX stock was attractively valued below $35. According to market observers, the assessment largely depends on whether the clinical studies proceed as planned. If study results are positive, analysts see significant upside potential for the stock price.

At the same time, observers pointed to potential obstacles that Viking Therapeutics must overcome on its path to potential market leadership in the obesity segment. These include intense competition from established pharmaceutical companies as well as the regulatory and commercial risks associated with developing new medications.

Long-Term Perspective for Investors

For long-term oriented investors, the progress of Phase-3 studies remains the central valuation factor. Viking Therapeutics has the opportunity to establish itself as a relevant player in the obesity market – but only if clinical data convince and the company overcomes regulatory hurdles.

The stock's volatility reflects the uncertainty inherent in biotech investments at this development stage. Investors must consider both the potential for significant stock gains if studies succeed and the risk of substantial losses if results are negative.